Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2311616 | 1.00 | HTR6 (0.51) | HTR6HTR2BCA12CA1CA2 | |
| SCHEMBL6885394 | 1.00 | HTR6 (0.51) | HTR6HTR2BCA12CA1CA2 | |
| SCHEMBL7997566 | 0.88 | HTR6 (0.55) | HTR6HTR2B | |
| SCHEMBL1178930 | 0.88 | HTR6 (0.55) | HTR6HTR2B | |
| SCHEMBL1178934 | 0.88 | HTR6 (0.55) | HTR6HTR2B | |
| SCHEMBL6885750 | 0.86 | HTR6 (0.64) | HTR6HTR2B | |
| SCHEMBL1178956 | 0.86 | HTR6 (0.64) | HTR6HTR2B | |
| SCHEMBL1178954 | 0.86 | HTR6 (0.64) | HTR6HTR2B | |
| SCHEMBL1179376 | 0.85 | HTR6 (0.53) | HTR6HTR2B | |
| SCHEMBL1179374 | 0.85 | HTR6 (0.53) | HTR6HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422244-B2 | Synthesis of substituted pyrazoline carboxamidine derivatives | ABBVIE BAHAMAS LTD. (BS) | 2016-08-23 | — | — | US | disclosed |
| EP-2528900-B1 | SYNTHESIS OF SUBSTITUTED PYRAZOLINE CARBOXAMIDINE DERIVATIVES | ABBVIE BAHAMAS LTD (BS) | 2014-06-11 | — | — | EP | disclosed |
| US-20130060041-A1 | SYNTHESIS OF SUBSTITUTED PYRAZOLINE CARBOXAMIDINE DERIVATIVES | ABBOTT HOSPITALS LIMITED (BS) | 2013-03-07 | — | — | US | disclosed |
| EP-2528900-A1 | SYNTHESIS OF SUBSTITUTED PYRAZOLINE CARBOXAMIDINE DERIVATIVES | Abbott Healthcare Products B.V. (NL) | 2012-12-05 | — | — | EP | disclosed |
| WO-2011092226-A1 | SYNTHESIS OF SUBSTITUTED PYRAZOLINE CARBOXAMIDINE DERIVATIVES | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060041-A1 | SYNTHESIS OF SUBSTITUTED PYRAZOLINE CARBOXAMIDINE DERIVATIVES | HTR6, HTR5A, HTR4 | HTR6 1/4885HTR2B 16/4885CA12 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.